DS-6000a for Kidney and Ovarian Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial requires an adequate treatment washout period (time without taking certain medications) before starting the study treatment, but it doesn't specify which medications need to be stopped. It's best to discuss your current medications with the trial team to understand what changes might be needed.
How is the drug DS-6000a different from other treatments for kidney and ovarian cancer?
The drug DS-6000a may offer a unique approach compared to standard treatments for ovarian cancer, as it could potentially be administered intraperitoneally (directly into the abdominal cavity), which has shown to enhance drug concentration and effectiveness in similar treatments like cisplatin and paclitaxel for ovarian cancer. This method can lead to better outcomes by increasing the drug's exposure to the tumor, which is not typically achieved with standard intravenous treatments.12345
What is the purpose of this trial?
This trial is testing a new medicine called R-DXd for patients with advanced kidney and ovarian cancers. The medicine targets cancer cells, gets inside them, and releases a drug that stops their growth and kills them. The study aims to find the safest dose and see how well it works.
Research Team
Global Clinical Leader
Principal Investigator
Daiichi Sankyo
Eligibility Criteria
This trial is for adults with advanced kidney cancer or ovarian tumors who can consent, use effective contraception, have a good performance status (able to carry out daily activities), and proper heart function. They must not have had certain previous cancer treatments, multiple cancers unless cured over 3 years ago, recent serious heart issues, significant lung illnesses, uncontrolled infections or brain metastases.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) receive an intravenous infusion of R-DXd to assess safety and determine the maximum tolerated dose
Dose Expansion
Participants receive R-DXd at the recommended dose to evaluate clinical activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DS-6000a
Find a Clinic Near You
Who Is Running the Clinical Trial?
Daiichi Sankyo
Lead Sponsor
Hiroyuki Okuzawa
Daiichi Sankyo
Chief Executive Officer
Degree in Social Sciences from Hitotsubashi University
Yuki Abe
Daiichi Sankyo
Chief Medical Officer since 2023
MD
Daiichi Sankyo, Inc.
Lead Sponsor
Yuki Abe
Daiichi Sankyo, Inc.
Chief Medical Officer since 2022
MD
Hiroyuki Okuzawa
Daiichi Sankyo, Inc.
Chief Executive Officer
Degree in Social Sciences from Hitotsubashi University
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University